IP Library Granted Patent US 9,650,432
Granted Patent B2
US 9,650,432 · App. 13/574,782 · Granted May 16, 2017

Rodent combinatorial antibody libraries

Inventors: Josef Prassler (Germering, DE); David Ott (München, DE); Stefanie Thiel (München, DE); Yvonne Stark (München, DE); Ute Keck (Basel, CH); Thomas Pietzonka (Basel, CH); Hilmar Ebersbach (Basel, CH)
Assignee: MORPHOSYS AG
C07K16/00C07K16/005C07K16/22C07K2317/20C07K2317/55C07K2317/56C07K2317/565C07K2317/73C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,650,432
App. No.
13/574,782
Granted
May 16, 2017
Kind
B2
Abstract

The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies.

Claims (38)

1. A synthetic rodent antibody or antibody fragment library of variable heavy (VH) and variable light (VL) chain combinations, wherein the VH-VL combinations consist of

a) VH1/Vk3,

b) VH2/Vk1, and

c) VH5/Vk3,

wherein a variable heavy chain or variable light chain comprises an amino acid sequence modification as compared to amino acid sequences encoded by germline genes, wherein said amino acid sequence modification results from modifying nucleic acids encoding the variable heavy chain or variable light chain to include a restriction site.

2. The library of claim 1 , wherein said rodent is selected from mouse and rat.

3. The library of claim 1 , wherein said library has a diversity of at least 1.0*10 8 in the H-CDR3 region.

4. The library of claim 1 , wherein said library is an unbiased library.

5. The library of claim 1 , wherein essentially all VH-VL combinations of said library are efficiently displayed as measured by sandwich phage ELISA.

6. The library of claim 1 , wherein essentially all VH-VL combinations comprise a thermal stability Tm of more than 62° C.

7. The library of claim 1 , wherein the nucleic acid sequences encoding the H-CDR3 regions of essentially all members of the library are flanked by nucleic acid sequences having unique restriction sites.

8. The library of claim 2 , wherein said mouse is selected from the laboratory strains Balb/c and C57BL/6.

9. The library of claim 1 ,

a) wherein VH1 is IGHV1-72*01 (SEQ ID NO: 179),

b) wherein VH2 is IGHV2-2*01 (SEQ ID NO: 181), and

c) wherein VH5 is IGHV5-9*04 (SEQ ID NO: 183).

10. The library of claim 1 ,

a) wherein Vk1 is IGKV1-117*01 (SEQ ID NO: 163), and

b) wherein Vk3 is selected from the group consisting of IGKV3-12*01 (SEQ ID NO: 164), and germline gene IGKV3-4*01 (SEQ ID NO: 166).

11. The library of claim 1 , wherein said library consists of the VH-VL combinations of

a) IGHV1-72*01 (SEQ ID NO: 179)/IGKV3-12*01 (SEQ ID NO: 164),

b) IGHV1-72*01 (SEQ ID NO: 179)/IGKV3-4*01 (SEQ ID NO: 166),

c) IGHV2-2*01 (SEQ ID NO: 181)/IGKV1-117*01 (SEQ ID NO: 163),

d) IGHV5-9*04 (SEQ ID NO: 183)/IGKV3-12*01 (SEQ ID NO: 164), and

e) IGHV5-9*04 (SEQ ID NO: 183)/IGKV3-4*01 (SEQ ID NO: 166).

12. The library of claim 1 , wherein said library comprises H-CDR3s of the length of 7-12 amino acids.

13. The library of claim 12 , wherein said library has a H-CDR3 design as shown in FIG. 5 or FIG. 6 .

14. The library of claim 1 , where the L-CDR3 of essentially all members of the library is of the length of 8 amino acids.

15. The library of claim 14 , wherein said library has a L-CDR3 design as shown in FIG. 7 or FIG. 8 .

16. The library of claim 1 , wherein said library has a diversity of at least 1.0*10 4 in the L-CDR3 region.

17. The library of claim 1 , wherein said library is a mouse library and at least one of amino acid residues 52, 52a, 54, 56 and 58 (Kabat numbering) of the H-CDR2 is diversified.

18. The library of claim 17 , wherein said library has a H-CDR2 design as shown in FIG. 10 or FIG. 11 .

19. The library of claim 1 , wherein said library has a diversity of at least 1.0*10 5 in the H-CDR2 region.

20. The library of claim 1 , wherein essentially all VH-VL combinations are expressed in E. coli in Fab format at levels of more than 5 mg/L.

21. The library of claim 1 , wherein essentially all VH-VL combinations are expressed in a mammalian system in IgG format at levels of more than 5 mg/L.

22. The library of claim 1 , wherein the nucleic acid sequences encoding the L-CDR3 regions of essentially all members of the library are flanked by nucleic acid sequences having unique restriction sites.

23. The library of claim 1 , wherein the nucleic acid sequences encoding the H-CDR2 regions of essentially all members of the library are flanked by nucleic acid sequences having unique restriction sites.

24. The library of claim 1 , wherein said modifications are selected from the group consisting of IGHV1-7201 with a Q1E mutation (SEQ ID NO: 179), IGHV 1-72*01 with a Q1E, a K67R and a A68V mutation (SEQ ID NO: 180), IGHV2-2*01 with a Q1E mutation (SEQ ID NO: 181), and IGHV5-9*04 with a K3Q mutation (SEQ ID NO: 183).

Assignments (2)
EXCERPT OF COMMERCIAL REGISTER REFLECTING NEW ADDRESS Recorded May 26, 2017
From: MORPHOSYS AG
To: MORPHOSYS AG
Reel/Frame 042587/0014 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2012
From: PRASSLER, JOSEF; THIEL, STEFANIE; OTT, DAVID; STARK, YVONNE; KECK, UTE; PIETZONKA, THOMAS; EBERSBACH, HILMAR; NOVARTIS PHARMA AG
To: MORPHOSYS AG
Reel/Frame 028618/0581 →
Priority Claims (1)
EP 10152164 · Jan 29, 2010 · regional
Continuity (2)
Provisional Application 61299380 · Jan 29, 2010
Related Publication 20130030157A1 · Jan 31, 2013